Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adaptimmune Therapeutics plc

https://www.adaptimmune.com/

Latest From Adaptimmune Therapeutics plc

ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies

An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.

ASCO ImmunoOncology

Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel

The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.

ASCO Biologics

Boehringer Explores ‘Dark Antigens’ With Enara In Potential $1bn Deal

Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.

Companies Commercial

Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko

Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.

Business Strategies Research and Development Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Adaptimmune LLC
    • Adaptimmune Ltd.
UsernamePublicRestriction

Register